Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching no evidence of disease activity (NEDA), according to a new analysis.

The study, “NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies,” was recently presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum, Feb. 23-25 in Orlando, Florida.

NEDA is a parameter that measures the absence of disease activity (in clinical settings and in magnetic resonance imaging) in MS patients. This parameter is increasingly recognized for its utility in clinical trials and is a potential goal for MS therapeutics.